Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
Scemblix (asciminib) is an allosteric inhibitor of BCR-ABL that binds to a unique location outside the ATP binding site, resulting in decreased BCR-ABL kinase activity and reduced tumor growth (PMID: 31543464, PMID: 31826340). Scemblix (asciminib) is FDA approved for use in patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) after two or more tyrosine kinase inhibitor treatments, and in adult patients with Ph+ CML in CP harboring ABL1 T315I (FDA.gov).
|DrugClasses||BCR-ABL Inhibitor 27|
|CAS Registry Number||1492952-76-7|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Asciminib + Dasatinib||Asciminib Dasatinib||0||2|
|Asciminib + Dasatinib + Prednisone||Asciminib Dasatinib Prednisone||0||1|
|Asciminib + Hydroxyurea + Ponatinib||Asciminib Hydroxyurea Ponatinib||0||0|
|Asciminib + Imatinib||Asciminib Imatinib||0||3|
|Asciminib + Nilotinib||Asciminib Nilotinib||0||3|
|Asciminib + Ponatinib||Asciminib Ponatinib||0||0|